Medpage Today on MSN7d
Overcoming the Challenges of Applying CAR T-Cell Therapy to Solid TumorsAn obvious next step in the development and growth of CAR T-cell therapies has been the jump to solid tumors. Because of ...
Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...
Leads developed LBL-051 using its antibody platform, dubbed LeadBody. The antibody binds to CD3 on T cells and CD19 and BCMA ...
The new Institute for Cell Therapy Discovery and Innovation will utilize expertise to develop cell therapies for cancer, autoimmune diseases, and infections.
News Medical on MSN6d
MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapiesThe University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & ...
The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a new ...
Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product candidate targeting B-cell maturation antigen ...
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback